Identification of a novel inhibitor of urokinase-type plasminogen activator

Molecular Cancer Therapeutics

Volumn 6, Issue 4, 2007, Pages 1348-1356

  Zhu, Ming ^a   Gokhale, Vijay M ^b   Szabo, Lajos ^b   Munoz, Ruben M ^a   Baek, Hyounggee ^b   Bashyam, Sridevi ^b   Hurley, Laurence H ^b   Von Hoff, Daniel D ^a   Han, Haiyong ^a  

^a TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [(5 OXO 2 PHENYL 4(5H) OXAZOLYLIDENE)METHYL]BENZENECARBOXIMIDAMIDE; AMILORIDE; ANTINEOPLASTIC AGENT; NS 47731; NS 47751; NS 47844; NS 47847; NS 47851; OXAZOLIDINONE DERIVATIVE; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEINASE INHIBITOR; SERINE PROTEINASE; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR; TRYPSIN; UK 122; UNCLASSIFIED DRUG; UROKINASE;

ARTICLE; CARCINOMA CELL; CELL INVASION; CELL MIGRATION; CHEMICAL MODIFICATION; CONCENTRATION RESPONSE; CYTOTOXICITY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; IC 50; METASTASIS POTENTIAL; MOLECULAR MODEL; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; STRUCTURE ANALYSIS;

CELL MOVEMENT; CELL PROLIFERATION; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HUMANS; MODELS, MOLECULAR; NEOPLASM INVASIVENESS; URINARY PLASMINOGEN ACTIVATOR;

EID: 34248189716     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0520     Document Type: Article

References (50)

1. Duffy MJ. The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des 2004;10:39-49.
2. Syrovets T, Simmet T. Novel aspects and new roles for the serine protease plasmin. Cell Mol Life Sci 2004;61:873-85.
3. 3 induces signal transduction and enhances plasminogen activation. Thromb Haemost 2006;95:524-34.
4. Kwak SH, Mitra S, Bdeir K, et al. The kringle domain of urokinase-type plasminogen activator potentiates lps-induced neutrophil activation through interaction with {α}v{β}3 integrins. J Leukoc Biol 2005;78: 937-45.
5. Bdeir K, Kuo A, Sachais BS, et al. The kringle stabilizes urokinase binding to the urokinase receptor. Blood 2003; 102:3600-8.
6. Irigoyen JP, Munoz-Canoves P, Montero L, Koziczak M, Nagamine Y. The plasminogen activator system: Biology and regulation. Cell Mol Life Sci 1999;56:104-32.
7. Castellino FJ, Ploplis VA. Structure and function of the plasminogen/ plasmin system. Thromb Haemost 2005;93:647-54.
8. Blasi F, Carmeliet P. UPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002;3:932-43.
9. Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000; 57:25-40.
10. Wang Y. The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis. Med Res Rev 2001;21:146-70.
11. Sordat B, Reiter L, Cajot JF. Modulation of the malignant phenotype with the urokinase-type plasminogen activator and the type I plasminogen activator inhibitor. Cell Differ Dev 1990;32:277-85.
12. Yang JL, Seetoo D, Wang Y, et al. Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets. Int J Cancer 2000;89:431-9.
13. Sidenius N, Blasi F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 2003;22:205-22.
14. Duffy MJ, Duggan C. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer. Clin Biochem 2004;37:541-8.
15. Salvi A, Arici B, De Petro G, Barlati S. Small interfering RNA urokinase silencing inhibits invasion and migration of human hepatocellular carcinoma cells. Mol Cancer Ther 2004;3:671-8.
16. Gondi CS, Lakka SS, Yanamandra N, et al. Expression of antisense uPAR and antisense uPA from a bicistronic adenoviral construct inhibits glioma cell invasion, tumor growth, and angiogenesis. Oncogene 2003; 22:5967-75.
17. Almholt K, Lund LR, Rygaard J, et al. Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice. Int J Cancer 2005;113:525-32.
18. Kellen JA, Mirakian A, Kolin A. Antimetastatic effect of amiloride in an animal tumour model. Anticancer Res 1988;8:1373-6.
19. Schweinitz A, Steinmetzer T, Banke IJ, et al. Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents. J Biol Chem 2004;279:33613-22.
20. Setyono-Han B, Sturzebecher J, Schmalix WA, et al. Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor wx-uk1. Thromb Haemost 2005; 93:779-86.
21. Rockway TW, Giranda VL. Inhibitors of the proteolytic activity of urokinase type plasminogen activator. Curr Pharm Des 2003;9: 1483-98.
22. Mackman RL, Hui HC, Breitenbucher JG, et al. 2-(2-Hydroxy-3-alkoxyphenyl)-1H-benzimidazole-5-carboxamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors. Bioorg Med Chem Lett 2002; 12:2019-22.
23. Bridges AJ, Lee A, Schwartz CE, Towle MJ, Littlefield BA. The synthesis of three 4-substituted benzo b]thiophene-2-carboxamidines as potent and selective inhibitors of urokinase. Bioorg Med Chem 1993;1: 403-10.
24. Barber CG, Dickinson RP, Fish PV. Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 3: 1-isoquinolinylguanidines. Bioorg Med Chem Lett 2004; 14:3227-30.
25. Heynekamp JJ, Hunsaker LA, Vander Jagt TA, Deck LM, Vander Jagt DL. Uncharged isocoumarin-based inhibitors of urokinase-type plasminogen activator. BMC Chem Biol 2006;6:1.
26. Vassalli JD, Belin D. Amiloride selectively inhibits the urokinase-type plasminogen activator. FEBS Lett 1987;214:187-91.
27. Barber CG, Dickinson RP. Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 2: (3-substituted-5-halo-2-pyridinyl)guanidines. Bioorg Med Chem Lett 2002;12:185-7.
28. Barber CG, Dickinson RP, Horne VA. Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 1: 2-pyridinylguanidines. Bioorg Med Chem Lett 2002;12:181-4.
29. Yang H, Henkin J, Kim KH, Greer J. Selective inhibition of urokinase by substituted phenylguanidines: quantitative structure-activity relationship analyses. J Med Chem 1990;33:2956-61.
30. Sperl S, Jacob U, Arroyo de Prada N, et al. (4-Aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase. Proc Natl Acad Sci U S A 2000;97:5113-8.
31. Todaro LB, Ladeda V, Bal de Kier Joffe E, Farias EF. Combined treatment with verapamil, a calcium channel blocker, and b428, a synthetic uPA inhibitor, impairs the metastatic ability of a murine mammary carcinoma. Oncol Rep 2003;10:725-32.
32. Xing RH, Mazar A, Henkin J, Rabbani SA. Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor b-428. Cancer Res 1997;57:3585-93.
33. Richter P, Wagner G. Synthesis of 3- and 4-amidinobenzaldehyde hydrochloride. Pharmazie 1978;33:39-41.
34. Katz BA, Mackman R, Luong C, et al. Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator. Chem Biol 2000;7:299-312.
35. Giese A, Rief MD, Loo MA, Berens ME. Determinants of human astrocytoma migration. Cancer Res 1994;54:3897-904.
36. Evans DM, Sloan-Stakleff K. Suppression of the invasive capacity of human breast cancer cells by inhibition of urokinase plasminogen activator via amiloride and b428. Am Surg 2000;66:460-4.
37. Katz BA, Luong C, Ho JD, et al. Dissecting and designing inhibitor selectivity determinants at the S1 site using an artificial Ala 190 protease (Ala 190 uPA). J Mol Biol 2004;344:527-47.
38. Wendt MD, Rockway TW, Geyer A, et al. Identification of novel binding interactions in the development of potent, selective 2-naphthamidine inhibitors of urokinase. Synthesis, structural analysis, and SAR of n-phenyl amide 6-substitution. J Med Chem 2004;47:303-24.
39. Richter P, Bubner M, Guethert I, Wagner G. Synthesis of 3-(4-amidinophenyl)-[1-14c]-pyruvic acid hydrochloride. Pharmazie 1981;36: 749-51.
40. Han H, Bearss DJ, Browne LW, et al. Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res 2002;62:2890-6.
41. Wang W, Abbruzzese JL, Evans DB, Chiao PJ. Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated rela. Oncogene 1999;18:4554-63.
42. Qu CF, Song EY, Li Y, at al. Pre-clinical study of 213bi labeled pai2 for the control of micrometastatic pancreatic cancer. Clin Exp Metastasis 2005;22:575-86.
43. Katz BA, Sprengeler PA, Luong C, et al. Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets. Chem Biol 2001;8:1107-21.
44. Myohanen H, Vaheri A. Regulation and interactions in the activation of cell-associated plasminogen. Cell Mol Life Sci 2004;61:2840-58.
45. Schoofs L, Clynen E, Salzet M. Trypsin and chymotrypsin inhibitors in insects and gut leeches. Curr Pharm Des 2002;8:483-91.
46. Yamashita K, Mimori K, Inoue H, Mori M, Sidransky D. A tumor-suppressive role for trypsin in human cancer progression. Cancer Res 2003;63:6575-8.
47. Nienaber VL, Richardson PL, Klighofer V, et al. Discovering novel ligands for macromolecules using X-ray crystallographic screening. Nat Biotechnol 2000;18:1105-8.
48. Nielsen A, Scarlett CJ, Samra JS, et al. Significant overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma using real-time quantitative reverse transcription polymerase chain reaction. J Gastroenterol Hepatol 2005;20:256-63.
49. Cantero D, Friess H, Deflorin J, et al. Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br J Cancer 1997;75:388-95.
50. Shin SJ, Kim KO, Kim MK, et al. Expression of e-cadherin and uPA and their association with the prognosis of pancreatic cancer. Jpn J Clin Oncol 2005;35:342-8